Takeda Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Takeda Pharmaceutical has a total shareholder equity of ¥7,274.0B and total debt of ¥4,843.8B, which brings its debt-to-equity ratio to 66.6%. Its total assets and total liabilities are ¥15,108.8B and ¥7,834.8B respectively. Takeda Pharmaceutical's EBIT is ¥493.2B making its interest coverage ratio 4.8. It has cash and short-term investments of ¥457.8B.
Key information
66.6%
Debt to equity ratio
JP¥4.84t
Debt
Interest coverage ratio | 4.8x |
Cash | JP¥457.80b |
Equity | JP¥7.27t |
Total liabilities | JP¥7.83t |
Total assets | JP¥15.11t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TAKP34's short term assets (¥2,558.6B) exceed its short term liabilities (¥2,313.1B).
Long Term Liabilities: TAKP34's short term assets (¥2,558.6B) do not cover its long term liabilities (¥5,521.7B).
Debt to Equity History and Analysis
Debt Level: TAKP34's net debt to equity ratio (60.3%) is considered high.
Reducing Debt: TAKP34's debt to equity ratio has reduced from 110.9% to 66.6% over the past 5 years.
Debt Coverage: TAKP34's debt is not well covered by operating cash flow (14.8%).
Interest Coverage: TAKP34's interest payments on its debt are well covered by EBIT (4.8x coverage).